Abbott Laboratories is a global healthcare company that operates in various segments, providing a wide range of products and services. The company focuses on branded generic pharmaceuticals, diagnostic systems and tests, nutritional products, and medical devices, catering to both international and domestic markets . Abbott's diversified portfolio includes significant contributions from emerging markets and innovations in medical devices, allowing it to maintain a balanced revenue stream across its segments .
- Medical Devices - Offers products in rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care, with the FreeStyle Libre system being a major growth driver .
- Established Pharmaceutical Products - Focuses on branded generic pharmaceuticals primarily sold in emerging markets, significantly contributing to international sales .
- Diagnostic Products - Includes a broad line of diagnostic systems and tests, with notable sales from COVID-19 testing, although this has decreased as the pandemic shifted to an endemic state .
- Nutritional Products - Encompasses both pediatric and adult nutrition, with products like Ensure and Glucerna leading growth, particularly in the U.S. market .
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Robert B. Ford ExecutiveBoard | Chairman of the Board and Chief Executive Officer | N/A | Robert B. Ford has been with Abbott since 2008, serving in various leadership roles. He became CEO in 2020 and Chairman in 2021. | View Report → |
Andrea Wainer Executive | Executive Vice President, Rapid and Molecular Diagnostics | N/A | Andrea Wainer has been with Abbott since 2015, leading the Rapid and Molecular Diagnostics division. | |
Daniel G. Salvadori Executive | Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | N/A | Daniel G. Salvadori has been with Abbott since 2014, serving in leadership roles in Nutritional Products and Pharmaceuticals. | |
Hubert L. Allen Executive | Executive Vice President, General Counsel, and Secretary | N/A | Hubert L. Allen joined Abbott in 2012 and has been EVP, General Counsel, and Secretary since 2013. | |
Lisa D. Earnhardt Executive | Executive Vice President and Group President, Medical Devices | N/A | Lisa D. Earnhardt joined Abbott in 2019 and has led the Medical Devices division, achieving significant financial metrics. | |
Louis H. Morrone Executive | Executive Vice President, Core Diagnostics | N/A | Louis H. Morrone joined Abbott in 2017 and has held senior roles in diagnostics. | |
Mary K. Moreland Executive | Executive Vice President, Human Resources | N/A | Mary K. Moreland joined Abbott in 2013 and has been EVP, Human Resources since 2019. | |
Philip P. Boudreau Executive | Senior Vice President, Finance and Chief Financial Officer | N/A | Philip P. Boudreau joined Abbott in 1997 and has held various finance leadership roles. He became CFO in 2023. | |
Claire Babineaux-Fontenot Board | Director | CEO of Feeding America; Founder of CBF Consulting Group, LLC; Director at New York Life Insurance Company | Claire Babineaux-Fontenot joined Abbott's board in 2022, bringing expertise in organizational governance and corporate finance. | |
Daniel J. Starks Board | Director | N/A | Daniel J. Starks has been a director at Abbott since 2017, with a background as Chairman, President, and CEO of St. Jude Medical. | |
Darren W. McDew Board | Director | Director at Parsons Corporation; Director at General Electric Company; Board member at USAA, Boys & Girls Club of America, and Manns Home Youth Foundation | Darren W. McDew has been a director at Abbott since 2019, with a background as a retired four-star general in the U.S. Air Force. | |
John G. Stratton Board | Director | Executive Chairman of Frontier Communications Parent, Inc.; Director at General Dynamics Corporation | John G. Stratton has been a director at Abbott since 2017, with extensive experience in telecommunications and corporate strategy. | |
Michael F. Roman Board | Director | Chairman and CEO of 3M Company; Director at 3M Company | Michael F. Roman has been a director at Abbott since 2021, with leadership experience in manufacturing and technology. | |
Michael G. O'Grady Board | Director | Chairman and CEO of Northern Trust Corporation; Director at Northern Trust Corporation | Michael G. O'Grady has been a director at Abbott since 2023, with expertise in financial services and corporate governance. | |
Michelle A. Kumbier Board | Director | Director at Teledyne Technologies Incorporated | Michelle A. Kumbier has been a director at Abbott since 2018, with extensive experience in manufacturing and strategic planning. | |
Nancy McKinstry Board | Lead Independent Director | CEO and Chairman of the Executive Board, Wolters Kluwer N.V.; Director at Accenture plc; Member of the Board of Overseers at Columbia Business School; Member of the European Round Table of Industrialists | Nancy McKinstry has been a director at Abbott since 2011, contributing her extensive global management experience. | |
Paola Gonzalez Board | Director | N/A | Paola Gonzalez has been a director at Abbott since 2021, with a background in corporate finance and strategic initiatives. | |
Robert J. Alpern Board | Director | Ensign Professor at Yale School of Medicine; Director at AbbVie Inc. and Tricida, Inc. | Robert J. Alpern has been a director at Abbott since 2008, contributing medical and scientific expertise. | |
Sally E. Blount Board | Director | President and CEO of Catholic Charities of the Archdiocese of Chicago; Michael L. Nemmers Professor of Strategy at Northwestern University; Director at the Joyce Foundation | Sally E. Blount has been a director at Abbott since 2011, bringing expertise in business organization and strategy. |
-
Given the competitive data expected in the tricuspid space and potential mortality benefits shown by competitors, how does Abbott plan to sustain growth in its structural heart franchises, particularly in the left atrial appendage closure and tricuspid markets?
-
With concerns about U.S. provider capacity potentially limiting growth in structural heart markets like TAVR, what strategies does Abbott have in place to mitigate potential bottlenecks and ensure continued adoption of its therapies?
-
Considering the strong statement from the FDA, CDC, and NIH regarding the lack of conclusive evidence linking infant formula to NEC, how does Abbott plan to address the ongoing lawsuits, and what measures are being taken to ring-fence liabilities related to these cases?
-
As recently launched products are expected to contribute about $1 billion in revenue this year, double that of 2023, what specific plans does Abbott have to sustain this momentum in innovation and revenue growth into 2025 and beyond?
-
With the expansion of the FreeStyle Libre system and the launch of Lingo for non-insulin-intensive type 2 diabetes patients, how does Abbott plan to navigate potential pricing pressures and maintain gross margins, especially as the market expands to a broader, price-sensitive population?
Research analysts who have asked questions during ABBOTT LABORATORIES earnings calls.
David Roman
Goldman Sachs Group Inc.
6 questions for ABT
Vijay Kumar
Evercore ISI
6 questions for ABT
Joanne Wuensch
Citigroup Inc.
5 questions for ABT
Travis Steed
Bank of America
5 questions for ABT
Danielle Antalffy
UBS Group AG
4 questions for ABT
Joshua Jennings
TD Cowen
4 questions for ABT
Larry Biegelsen
Wells Fargo & Company
4 questions for ABT
Robert Marcus
JPMorgan Chase & Co.
3 questions for ABT
Marie Thibault
BTIG
2 questions for ABT
Matthew Miksic
Barclays PLC
2 questions for ABT
Robbie Marcus
JPMorgan Chase & Co.
2 questions for ABT
Suraj Kalia
Oppenheimer & Co. Inc.
2 questions for ABT
Adam Maeder
Piper Sandler Companies
1 question for ABT
Danielle Joy Antalffy
UBS Investment Bank
1 question for ABT
Josh Jennings
TD Cowen
1 question for ABT
Joshua Thomas Jennings
TD Cowen
1 question for ABT
Lawrence Biegelsen
Wells Fargo
1 question for ABT
Lawrence H. Biegelsen
Wells Fargo Securities
1 question for ABT
Matt Miksic
Barclays Investment Bank
1 question for ABT
Robert Justin Marcus
JPMorgan Chase & Co.
1 question for ABT
Travis Lee Steed
BofA Securities
1 question for ABT
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Bigfoot Biomedical, Inc. | 2023 | Abbott completed the acquisition on September 22, 2023, aimed at enhancing connected solutions for more personalized and precise diabetes management, with the purchase price and asset allocation deemed not material to its financial statements. |
Cardiovascular Systems, Inc. | 2023 | Abbott acquired CSI on April 27, 2023 for approximately $851 million (at $20 per common share), adding its atherectomy system and complementary technologies to its vascular portfolio with significant intangible assets and goodwill recognized in the transaction. |
Walk Vascular, LLC | 2021 | In September 2021, Abbott acquired Walk Vascular to integrate its JETi thrombectomy system into its portfolio, targeting expansion in the high-growth peripheral thrombectomy market and planning to secure a pulmonary embolism indication. |
Recent press releases and 8-K filings for ABT.
- Revenue of $11.4 B, up 7.5% on an organic basis (GAAP sales +6.9%)
- Adjusted diluted EPS of $1.30; GAAP diluted EPS of $0.94
- Reaffirmed full-year adjusted EPS guidance of $5.12–$5.18 and organic sales growth of 7.5%–8.0%
- Segment sales: Medical Devices $5.4 B, Diagnostics $2.3 B, Established Pharmaceuticals $1.5 B, Nutrition $2.2 B
- Key business highlights include CE Mark for expanded Navitor indication, Japan approval for TriClip, and a global blood donation initiative
- Organic sales rose 7.5% excluding COVID test sales, led by Medical Devices growth of 12.5%, Nutrition up 4%, Established Pharmaceuticals up 8%, Diagnostics excluding COVID up mid‐single digits and EPD up 7%.
- Q3 EPS was $1.30, up high single digits versus prior year and up double digits ex‐COVID test decline.
- Recently launched products generated nearly $500 M in Q3 sales and contributed over 100 bps to organic growth.
- Diabetes care device sales of continuous glucose monitors totaled $2.0 B, a 17% increase year-over-year.
- Company reaffirmed full-year guidance of high single digit organic sales growth and double digit EPS growth.
- Reported 7.5% organic sales growth excluding COVID-19 test sales and EPS of $1.30, up high single digits YoY (double-digit ex-COVID).
- Nutrition sales rose 4%, led by adult nutrition growth; Diagnostics saw modest growth ex-COVID but faced headwinds in China pricing and volume.
- Established Pharmaceuticals sales increased 7%, driven by double-digit growth in key 15 markets; Medical Devices sales grew 12.5%, with diabetes care at $2 billion (+17%) and double-digit gains in EP, CRM, heart failure, and structural heart.
- Highlighted recent product launches (Volt PFA catheter, Triclip in Japan, NAVATOR TAVR expanded CE mark) and reiterated outlook for high single-digit organic sales growth and double-digit EPS growth in 2026.
- Sales grew 6.9% year-over-year to $11.369 billion, with organic growth of 5.5% (7.5% excluding COVID-19 testing).
- GAAP diluted EPS was $0.94, and adjusted diluted EPS was $1.30, reflecting strong operating performance.
- Reaffirmed full-year 2025 organic sales guidance of 7.5–8.0% (6.0–7.0% including COVID-19 testing) and narrowed adjusted EPS guidance to $5.12–$5.18.
- Declared a $0.59 quarterly dividend, marking the 407th consecutive dividend, payable Nov. 17, 2025.
- Abbott posted 6.9% reported and 5.5% organic sales growth in Q3 2025 (7.5% excluding COVID-19 testing).
- Third-quarter GAAP diluted EPS was $0.94; adjusted EPS was $1.30, and adjusted operating margin rose 40 bps to 23.0%.
- Abbott reaffirmed its full-year 2025 guidance: 7.5–8.0% organic sales growth (6.0–7.0% including COVID-19 testing) and narrowed adjusted EPS to $5.12–$5.18.
- The company received regulatory approval for TriClip in Japan and a CE Mark for expanded Navitor TAVI indications.
- Steven Tahmooressi joins Insight Molecular Diagnostics as Vice President of Marketing to lead global marketing for the GraftAssure family of assays, drawing on 25 years of experience at Astellas, Abbott and Bristol-Myers Squibb.
- He will spearhead the launch of GraftAssureDx, the company’s first clinical kitted transplant rejection test kit, slated for FDA authorization in 2026.
- iMDx targets a $1 billion addressable market for kitted transplant rejection testing, aiming to expand access to dd-cfDNA assays globally.
- The company relocated its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025 and changed its Nasdaq ticker to IMDX on June 18, 2025.
- The US continuous glucose monitoring market is projected to grow from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033 at a CAGR of 8.36%.
- Growth is driven by rising diabetes prevalence—over 38 million Americans affected—advances in CGM technology, and increasing insurance reimbursement, including Medicare expansion.
- In June 2024, Abbott received FDA approval for two over-the-counter CGM systems, LingoT and Libre RioT, aimed at enhancing user accessibility.
- Key challenges include high device and sensor costs and user compliance issues, such as alarm fatigue and sensor-related frustrations.
- H1 2025 revenue rose to €2.85 M, up from €2.73 M in H1 2024, driven by a 73% increase in HIV product sales to €1.20 M
- Net income for the period turned positive at €288,677, reflecting improved cost control and profitability
- Operating income (produits d’exploitation) reached €3.33 M, with cash flow from operations of €606,470 and a net cash position of €1.77 M at June 30, 2025
- Active distributors increased to 72, up 53% from year-end 2024, bolstering international reach
- Abbott’s Navitor TAVI system received CE Mark in Europe to treat symptomatic, severe aortic stenosis in low- and intermediate-risk patients, extending its prior high/extreme-risk approval to all surgical risk categories.
- The expanded indication is based on VANTAGE trial data showing in 262 patients at 12 months a 2.3% rate of all-cause mortality or fatal stroke, 0% moderate or greater paravalvular leak at 30 days, and a 97% technical success rate.
- This approval significantly broadens the eligible patient population for minimally invasive TAVI therapy across Europe.
- Abbott Labs kicked off trading by ringing the opening bell at the NYSE and will host CEO Robert Ford at 10 a.m. to discuss strategic priorities, including potential impacts from President Trump’s tariffs.
- Traders are jittery ahead of Nvidia’s earnings, with the stock up 35% year-to-date and options markets implying a ±6% move on the report.
- PVH Corp and Abercrombie & Fitch cited significant tariff-related profit hits—$1.15 EPS for PVH and $90 million for Abercrombie—while outlining mitigation measures in their latest results.
- Constellation Brands shares, down 28% year-to-date and nearing a 52-week low, were downgraded to underperform on concerns over changing consumer behavior and GLP-1 drug impacts.
- Cracker Barrel reversed its recent logo redesign after social media backlash and political criticism, adding scrutiny to CEO Julie Masino’s three-year transformation plan.